Author: Tris Pharma, Inc.

Posted Date:

May 5, 2026

Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer

Tris Pharma, Inc.

May 5, 2026
Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix

Tris Pharma, Inc.

April 8, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting

Tris Pharma, Inc.

March 6, 2026